Your browser doesn't support javascript.
loading
KMT2C expression and DNA homologous recombination repair factors in lung cancers with a high-grade fetal adenocarcinoma component.
Suzuki, Masaki; Kasajima, Rika; Yokose, Tomoyuki; Shimizu, Eigo; Hatakeyama, Seira; Yamaguchi, Kiyoshi; Yokoyama, Kazuaki; Katayama, Kotoe; Yamaguchi, Rui; Furukawa, Yoichi; Miyano, Satoru; Imoto, Seiya; Shinozaki-Ushiku, Aya; Ushiku, Tetsuo; Miyagi, Yohei.
Afiliación
  • Suzuki M; Department of Pathology, The University of Tokyo, Tokyo, Japan.
  • Kasajima R; Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan.
  • Yokose T; Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
  • Shimizu E; Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Hatakeyama S; Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan.
  • Yamaguchi K; Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Yokoyama K; Division of Clinical Genome Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Katayama K; Division of Clinical Genome Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Yamaguchi R; Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Furukawa Y; Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Miyano S; Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Imoto S; Division of Cancer Systems Biology, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Shinozaki-Ushiku A; Division of Cancer Informatics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Ushiku T; Division of Clinical Genome Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Miyagi Y; Division of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Transl Lung Cancer Res ; 12(8): 1738-1751, 2023 Aug 30.
Article en En | MEDLINE | ID: mdl-37691868
Background: High-grade fetal adenocarcinoma of the lung (H-FLAC) is a rare variant of pulmonary adenocarcinoma. Our previous study showed a high frequency of KMT2C mutations in lung cancers with an H-FLAC component, showing that KMT2C dysfunction may be associated with the biological features of H-FLACs. Methods: In this study, we performed RNA sequencing and immunohistochemical analysis to identify the differentially expressed genes and corresponding pathways associated with H-FLACs, compared with common adenocarcinomas. Results: Ingenuity pathway analysis based on RNA sequencing data revealed that DNA homologous recombination repair (HRR) pathways were significantly inactivated in H-FLAC. Expression of KMT2C, ATM, ATR, and BRCA2 was significantly lower in H-FLACs than in common adenocarcinomas, and BRCA1 expression showed a decreasing trend. Pearson correlation analyses for all cases revealed that KMT2C expression showed a strong positive correlation (R>0.7) with the expression of ATR, BRCA1, and BRCA2 genes and a moderately positive correlation with ATM expression (R=0.47). Immunohistochemical analysis showed significantly lower levels of KMT2C, ATM, ATR, and BRCA2 expression in H-FLACs than in common adenocarcinomas, and a trend of lower BRCA1 levels. Additionally, KMT2C expression showed a weak to moderate correlation with that of ATM, ATR, BRCA1, and BRCA2. Conclusions: Cancers containing H-FLAC components showed lower levels of KMT2C and HRR factors than common lung adenocarcinomas, and their levels exhibited a positive correlation. These results support the hypothesis that loss of KMT2C function decreases the expression of the HRR factors in H-FLACs. H-FLACs with low KMT2C expression may be a good indication for poly (ADP-ribose) polymerase (PARP) inhibitor-based therapy.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Transl Lung Cancer Res Año: 2023 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Transl Lung Cancer Res Año: 2023 Tipo del documento: Article País de afiliación: Japón